AUTHORS
Thura Win Htut, MD, FRCPath, Charan Thej Reddy Vegivinti, MD, MBBS2, Guillermo Montalban-Bravo, MD3, Kelly Sharon Chien, MD4, Alex Bataller, MD, PhD5, Alexandre Bazinet, MD, MSc6, Mahesh Swaminathan, MD7, Wei Ying Jen, BM BCh, FRCPath8, Gautam Borthakur, MD9, Courtney DiNardo, MD, MSCE10, Yesid Alvarado Valero, MD11, Farhad Ravandi, MD12, Naval Daver, MD13, Elias Jabbour, MD14, Abhishek Maiti, MBBS15, Nicholas Short, MD16, Ghayas C. Issa, MD17, Tapan Kadia I, MD18, Naveen Pemmaraju, MD19, Hannah Goulart, MD20, Jennifer Marvin-Peek, MD21, Guillermo Garcia-Manero, MD22, Ian Bouligny, M.D.23
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
The International Working Group (IWG) 2023 response criteria for higher-risk MDS (HR-MDS) introduced new response categories, including CR with limited count recovery (CRL; including CR with bilineage [CRbi] and unilineage [CRuni] count recovery) and CR with partial hematologic recovery (CRh), and eliminated marrow CR to better capture clinically meaningful outcomes. We sought to determine whether IWG 2023 response independently predicts overall survival (OS) in HR-MDS patients receiving frontline hypomethylating agent (HMA) therapy.
Methods
We performed a retrospective analysis of patients aged ≥18 years with HR-MDS (IPSS-R ≥3.5 and/or IPSS-M moderate-high, high, or very-high risk) treated with frontline azacitidine or decitabine at MD Anderson Cancer Center (2014-2025), combining patients treated on and off clinical trial protocols. Responses were assessed per IWG 2023 criteria. OS was estimated by Kaplan-Meier method and compared by log-rank test. Multivariable logistic regression identified predictors of IWG 2023 response. Multivariable Cox regression assessed whether IWG 2023 response independently predicted OS after adjusting for age, ECOG, TP53 mutation status, and complex cytogenetics.
Results
Of 263 HR-MDS patients, 205 were evaluable for IWG 2023 response. Median age was 71 years (IQR, 64–76); 72% had ECOG 0–1. By IPSS-M (n=185 evaluable), 32% were moderate-high, 38% high, and 30% very-high risk. Baseline transfusion dependence was present in 55%, complex cytogenetics in 25%, and TP53 mutations in 28%. Frontline therapy was azacitidine in 47% and decitabine in 53%.
At median follow-up of 59.7 months, median OS for the entire cohort was 19.1 months (95% CI, 16.7–26.5). AML transformation occurred in 27%. By IWG 2023 criteria, the overall response rate was 50% (103/205): CR 17 (8%), CRbi12 (6%), CRuni 9 (4%), CRh 16 (8%), and HI 49 (24%). Responders had significantly longer median OS than non-responders (32.8 vs. 17.6 months; P<0.001). IWG 2023 response categories significantly stratified OS (P=0.006): CR 28.5 months, CRbi 55.2 months, CRh 35.8 months, and HI 33.6 months, compared with 17.6 months for non-responders and 15.9 months for CRuni (limited by n=9). Longer OS in the HI group than the CR group reflects baseline response eligibility rather than depth of response: CR requires excess marrow blasts at baseline, whereas HI responders largely had <5% blasts and were therefore lower-risk in this high-risk cohort.
In multivariable Cox regression, IWG 2023 response independently predicted OS (HR 0.58, 95% CI, 0.40-0.85; P=0.006) after adjusting for age, ECOG, complex karyotype, and mutated TP53. In multivariable logistic regression controlling for age, IPSS-M risk, ECOG, transfusion dependence, and HMA type, increasing IPSS-M risk independently predicted lower odds of achieving IWG 2023 response (OR 0.67; 95% CI, 0.45–0.97; P=0.036).
Conclusions
In this validation of the IWG 2023 criteria, response independently predicted OS beyond established clinical and molecular risk factors in HMA-treated HR-MDS. Sub-CR categories (CRbi, CRh) were associated with favorable survival, supporting their inclusion as clinically meaningful endpoints. Higher IPSS-M risk independently predicted lower odds of response. These data establish real-world benchmarks for IWG 2023 response rates and category-specific survival to inform future trial design.
DISCLOSURES
Thura Win Htut, MD, FRCPath: No relevant conflicts of interest to declare.